23%

Improvement in Medication Adherence Rate

33%

Capture of Quality of Life Score

47%

Reduction in EEG Abnormality Rate

44%

Increase in Neurologist Consultation Rate

Centralizes comparative insights on healthcare utilization and costs for long-acting (LA) vs. short-acting (SA) antiepileptic drug (AED) monotherapy. With detailed reports on drug effectiveness and patient outcomes, it empowers R&D professionals, scientists, and healthcare leaders to accelerate pharma business decisions through concrete, data-driven findings.

Frequently asked questions

It compares healthcare utilization, costs, and patient outcomes across treatment options, such as long-acting versus short-acting antiepileptic drug monotherapy, to give R&D and pharma teams evidence rather than assumption.

Utilization and cost patterns often differ meaningfully between dosing formats; comparing them directly surfaces which option delivers better outcomes per healthcare dollar spent.

R&D professionals, scientists, and healthcare leaders making decisions about treatment positioning, market access, or further drug development investment.

Business and clinical decisions about which therapy formats to prioritize, based on concrete utilization and outcome data rather than published trial results alone.

No. It complements trial data with real-world utilization and cost evidence, which trials are not designed to capture at this level of operational detail.

By structuring healthcare utilization and outcomes data into a BI platform through Business Analytics services, informed by Life Sciences industry work.